Penghua SSE STAR Biology and Medicine ETF

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

BeiGene's Brukinsa Approved by FDA

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

Belayidiantianheng Receives Approval for Clinical Trials of Iza-bren Combination Therapy

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BeOne Medicines released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue CNY 10.46 B (forecast CNY 9.93 B), actual EPS CNY 1.0368

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BrightGene released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 324.93 M, actual EPS CNY 0.02

BeOne Medicines to Release FY2026 Q1 Earnings on May 6 Pre-Market (BJT), Forecast Revenue CNY 9.835 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

Zelgen released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 905.39 M, actual EPS CNY 2.39

159615

516500

588250

159849

512290

159859

159102

159837

516930

Nanjing's Leads Biolabs Co., Ltd. revealed today that their exclusive PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has been approved by the Center for Drug Evaluation. This announcement was made under the Stock Code.

Unusual Whales

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

LEADS BIOLABS-B

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. announced that its PD-L1/4-1BB bispecific antibody, Opamtistomig, has received approval for a pivotal Phase III trial for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). This marks a shift from late-line to first-line treatment, expanding its patient population. The study, led by Professor Lin Shen, aims to validate Opamtistomig's potential to improve patient survival. The company plans to submit a Biologics License Application in Q3 2026 and is advancing multiple trials across various solid tumor indications.

prnewswire

21:35 ETLeads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

01801

159316

159570

512010

159892

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

ARKG

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

VG Health

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

BlackRock, Inc.

iShares US Pharma

iShares Global Healthcare

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

Tip Ranks

REMEGEN

RemeGen

Bosera Hang Seng Health Care ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

Kali Therapeutics announced that preclinical data for KT502, a novel CD19 x CD3 T-cell engager, will be presented at the EULAR 2026 Annual Congress in London. KT502 aims to provide deep B-cell depletion for autoimmune diseases with a favorable safety profile. The presentation is scheduled for June 4, 2026, highlighting its potential therapeutic benefits and the company's progress in expanding its clinical pipeline following the initiation of KT501.

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

07:01 ETKali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

02268

WXXWY

02269

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Microbiotica reports positive results for MB097 in advanced melanoma

China's 12th batch of centralized drug procurement will include over 70 varieties and 233 specifications, marking a record high. This batch introduces a pre-filing mechanism for transparency. Major drugs like Entresto, with annual sales of CNY8 billion, face intense competition. The new medical insurance policy limits reimbursements to procurement prices, influencing patient choices towards lower-priced options. The National Healthcare Security Administration plans to enhance procurement rules to foster competition among enterprises.

Yicai

China’s 12th Batch of Centralized Drug Procurement to Cover Record Number of Varieties

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Penghua SSE STAR Biology and Medicine ETF(588250.SH)